{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:09:14Z","timestamp":1790662154495,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.cca.2012.09.026","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T13:30:52Z","timestamp":1349184652000},"page":"273-280","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["LC\u2013MS\/MS analysis of plasma lyso-Gb3 in Fabry disease"],"prefix":"10.1016","volume":"414","author":[{"given":"Michel","family":"Boutin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2012.09.026_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cca.2012.09.026_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cca.2012.09.026_bb0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.cca.2012.09.026_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2012.09.026_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cca.2012.09.026_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A \u2014 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2012.09.026_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cca.2012.09.026_bb0040","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/rcm.728","article-title":"Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson\u2013Fabry disease","volume":"16","author":"Boscaro","year":"2002","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.cca.2012.09.026_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2012.09.026_bb0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2012.09.026_bb0055","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/rcm.1948","article-title":"Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard","volume":"19","author":"Fauler","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.cca.2012.09.026_bb0060","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2012.09.026_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2012.09.026_bb0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid chromatography\u2013tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy","volume":"51","author":"Roddy","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2012.09.026_bb0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2012.09.026_bb0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2012.09.026_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","article-title":"Gb3\/creatinine biomarkers for Fabry disease: issues to consider","volume":"97","author":"Auray-Blais","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2012.09.026_bb0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2012.09.026_bb0095","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1016\/j.cca.2012.09.026_bb0100","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.cca.2012.09.026_bb0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"3,399","author":"Togawa","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cca.2012.09.026_bb0110","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.cca.2012.09.026_bb0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cca.2012.09.026_bb0120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"Kr\u00fcger","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2012.09.026_bb0125","series-title":"Fabry Disease","first-page":"111","article-title":"Laboratory diagnosis of Fabry disease","author":"Winchester","year":"2010"},{"key":"10.1016\/j.cca.2012.09.026_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cca.2012.09.026_bb0135","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bbalip.2011.06.027","article-title":"Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry (LC\u2013MS\/MS) and tissue imaging mass spectrometry (TIMS)","volume":"1811","author":"Sullards","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cca.2012.09.026_bb0140","unstructured":"Mirzain M. The development of an UPLC\u2013MS\/MS method for determination of lysoglobotriaosylceramide (lyso-Gb3) and (lyso)-sulfatide in body fluids and tissues from patients with Fabry disease and metachomatic leukodystrophy (MLD). Master Chemistry Thesis, Analytical Sciences, University of Amsterdam, March 2011, http:\/\/www.science.uva.nl\/onderwijs\/thesis\/centraal\/files\/f783234087.pdf."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898112004615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898112004615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T06:20:00Z","timestamp":1542694800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898112004615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":28,"alternative-id":["S0009898112004615"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2012.09.026","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}